UnknownPhase 4

Effect of RAS Blockers on CKD Progression in Elderly Patients With Non Proteinuric Nephropathies (PROERCAN01)

Spain106 participantsStarted 2015-06

Plain-language summary

This study evaluates the effect of renin-angiotensin blockers on chronic kidney disease progression in elderly (\>65 years old) patients with non-proteinuric nephropathies. Half of the patients will receive angiotensin converting enzyme inhibitors, while the other half will not receive them. Renal function, proteinuria and cardiovascular events will be follow up during a three year period.

Who can participate

Age range65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. patients who have not received RAS blockers in the three months prior to inclusion can be included
✓. patients who are receiving RAS blockers could be included after one month washout period

What they're measuring

Chronic kidney disease progression

Timeframe: 3 years

Trial details

NCT IDNCT03195023

SponsorHospital General Universitario Gregorio Marañon

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-12

Contact for this trial

Maria Angeles Goicoechea, PhD, MD

0034609838684 marian.goicoechea@gmail.com

View on ClinicalTrials.gov More Renal Insufficiency, Chronic trials